Drug Profile
TBS 6
Alternative Names: TBS-6Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Trimel Pharmaceuticals Corporation
- Developer Acerus Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Allergic rhinitis
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Canada (Intranasal, Spray)
- 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
- 04 Mar 2015 Preclinical development is ongoing in Canada